{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:02:00Z","timestamp":1780452120921,"version":"3.54.1"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Sodium\u2010glucose cotransporter 2 (<jats:styled-content style=\"fixed-case\">SGLT<\/jats:styled-content>2) inhibitors are used in the treatment of human diabetics. They increase glucose excretion and correct hyperglycemia. We examined the investigational<jats:styled-content style=\"fixed-case\">SGLT<\/jats:styled-content>2 inhibitor velagliflozin in two groups of six neutered adult obese cats (equal gender distribution). Placebo (Pl) or drug (D; 1\u00a0mg\/kg) was administered for 35\u00a0days. Routine blood examinations, fructosamine, beta\u2010hydroxybutyrate (<jats:styled-content style=\"fixed-case\">BHB<\/jats:styled-content>), nonesterified fatty acids (<jats:styled-content style=\"fixed-case\">NEFA<\/jats:styled-content>), glucagon, adiponectin, and leptin were measured before and after treatment, also water intake, and urinary electrolytes, glucose, and volume. Indirect calorimetry, an intravenous glucose tolerance test (<jats:styled-content style=\"fixed-case\">IVGTT<\/jats:styled-content>; 0.8\u00a0g\/kg) and insulin tolerance test (<jats:styled-content style=\"fixed-case\">IVITT<\/jats:styled-content>) were conducted. All cats tolerated treatment well. Significant changes with D included a decrease in the respiratory exchange ratio, an increase in cholesterol, a small increase in albumin, and a rise in<jats:styled-content style=\"fixed-case\">BHB<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">NEFA<\/jats:styled-content>. Glucose clearance was unaltered, although less insulin was secreted during the<jats:styled-content style=\"fixed-case\">IVGTT<\/jats:styled-content>(<jats:italic>p<\/jats:italic>\u00a0=\u00a0.056) suggesting improved insulin sensitivity.<jats:styled-content style=\"fixed-case\">IVITT<\/jats:styled-content>was unchanged. Treatment did not affect glucagon, leptin, or adiponectin. Water intake, urine output, urinary glucose excretion, and the glucose\/creatinine ratio but not urinary electrolytes were significantly higher post\u2010D. We conclude that velagliflozin is a promising drug, which increases urinary glucose excretion in cats and could thereby be beneficial for the treatment of hyperglycemia.<\/jats:p>","DOI":"10.1111\/jvp.12467","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T05:23:07Z","timestamp":1510723387000},"page":"266-273","source":"Crossref","is-referenced-by-count":29,"title":["Effects of the sodium\u2010glucose cotransporter 2 (<scp>SGLT<\/scp>2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-4635","authenticated-orcid":false,"given":"M.","family":"Hoenig","sequence":"first","affiliation":[{"name":"Department of Clinical Veterinary Medicine College of Veterinary Medicine University of Illinois Urbana IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Clark","sequence":"additional","affiliation":[{"name":"Comparative Biosciences College of Veterinary Medicine University of Illinois Urbana IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Schaeffer","sequence":"additional","affiliation":[{"name":"Comparative Biosciences College of Veterinary Medicine University of Illinois Urbana IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Reiche","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Vetmedica GmbH Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.87"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.510"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74297"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3180"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12255"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2143\/ACB.3349"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2460\/javma.1997.210.06.772","article-title":"Intensive 50\u2010week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus","volume":"15","author":"Feldman E. C.","year":"1997","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1088"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12214"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00115.2012"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1472"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mco.0000241668.30761.69"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci1020121"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800101-1.00012-0"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64852-3"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00342.2011"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00982.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.90771.2008"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.250"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.04.003"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.031"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70704"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0642"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2004.tb00130.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2014.04.006"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors","volume":"7","author":"Ogawa W.","year":"2015","journal-title":"Journal of Diabetes Investigation"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.9.1794"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3427"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.13817"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112981"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_2_7_38_1","unstructured":"U.S. Food and Drug Administration(2015).Drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood[Internet]. Retrieved fromhttp:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM446954.pdf"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1040638711428332"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.01.040"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12467","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T17:11:15Z","timestamp":1719594675000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/jvp.12467"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12467","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]}}}